STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co Inc - MRK STOCK NEWS

Welcome to our dedicated news page for Merck & Co (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co's position in the market.

News
Merck Announces First-Quarter 2024 Financial Results
Rhea-AI Summary
Merck reported strong financial results for the first quarter of 2024, with total worldwide sales reaching $15.8 billion, a 9% increase from the previous year. Key products like KEYTRUDA and GARDASIL/GARDASIL 9 experienced significant sales growth. The company received FDA approval for WINREVAIR, a treatment for pulmonary arterial hypertension. Merck also made progress in various therapeutic areas, expanded its pipeline through acquisitions, and provided a positive full-year 2024 financial outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
earnings
-
News
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Rhea-AI Summary
Merck (MRK) initiates Phase 3 trial for MK-1084 in combination with KEYTRUDA for first-line treatment of metastatic NSCLC patients with KRAS G12C mutations and PD-L1 expression. The trial aims to evaluate efficacy and safety in previously untreated patients with promising early results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
clinical trial
-
News
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Rhea-AI Summary
Daiichi Sankyo and Merck announce the dosing of the first patient in the REJOICE-Ovarian01 trial for investigational drug R-DXd in platinum-resistant ovarian cancer. The trial aims to evaluate the drug's efficacy compared to chemotherapy in patients with advanced ovarian cancer, addressing the critical need for innovative therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
clinical trial
News
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Rhea-AI Summary
Merck (MRK) to host first-quarter 2024 sales and earnings conference call on April 25, providing an overview of the company's performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
earnings
-
News
How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together
Rhea-AI Summary
Merck leaders discuss efforts to address vaccine-preventable illnesses and combat vaccine hesitancy, emphasizing collaboration and equity to improve global vaccination programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
News
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Rhea-AI Summary
Merck's KEYTRUDA receives EC approval for neoadjuvant and adjuvant treatment in resectable NSCLC in Europe, marking the first anti-PD-1/L1 therapy approved for this indication. The approval is based on positive overall survival results from the Phase 3 KEYNOTE-671 trial, showing significant improvements in OS and EFS. This milestone expands KEYTRUDA's indications to six in NSCLC and 27 overall in the EU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
News
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Rhea-AI Summary
Merck (MRK) receives FDA approval for WINREVAIR, a breakthrough therapy for pulmonary arterial hypertension (PAH), showing significant clinical benefits in improving exercise capacity and reducing clinical worsening events. WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, offering a new treatment pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
fda approval
-
News
Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region
Rhea-AI Summary
The Merck Foundation, funded by Merck (NYSE:MRK), commits $11 million over six years to support healthcare in underserved communities, training 33,000 local health workers in India, Indonesia, Malaysia, and Vietnam. This builds on a previous $7 million commitment to improve access to specialty care for chronic conditions in India and Vietnam.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
News
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Rhea-AI Summary
Merck's Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA in combination with LYNPARZA did not meet primary endpoints for certain patients with metastatic nonsquamous NSCLC. Safety profiles were consistent, and further data evaluation is ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
clinical trial
News
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Rhea-AI Summary
Merck (MRK) announces positive data from Phase 3 trials of V116, a potential pneumococcal conjugate vaccine for adults, at the 13th ISPPD meeting. V116 shows immunogenicity across various adult populations and higher immune responses for unique serotypes. FDA granted V116 priority review with a PDUFA date of June 17, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
Stock MRK logo
Merck & Co Inc

NYSE:MRK

MRK Rankings

#23 Ranked by Market Cap
#1895 Ranked by Stock Gains
#1294 Ranked by Dividends

MRK Stock Data

318.50B
2.53B
0.05%
78.56%
0.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Kenilworth

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.